Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 5, 2014, Pages 426-443

  Han, Shuang ^a   Chen, Jiong Jiong ^a   Chen, Jian Zhong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cannabinoid receptors; CB2; GPCRs; Selective ligand; Structure activity relationship

Indexed keywords

1 [4 (PYRIDIN 2 YL)BENZYL]IMIDAZOLIDINE 2,4 DIONE DERIVATIVE; 1,2,3 TRIAZOLE; 1,4 DIAZEPANE; 2 PYRIDONE DERIVATIVE; 2,4 DIPHENYL 1H IMIDAZOLE DERIVATIVE; 2,4,6 TRISUBSTITUTED 1,3,5 TRIAZINE; 4 QUINOLONE DERIVATIVE; ADAMANTYL DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BISAMIDE DERIVATIVE; CANNABINOID 2 RECEPTOR; DECAHYDROQUINOLINE AMIDES; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; JTE 907; LIGAND; NABIXIMOLS; OTENABANT; OXADIAZOLE; PURINE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; S 777469; SULFAMOYL BENZAMIDE; SULFONAMIDE; SYNTHETIC LIGAND; TARANABANT; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST;

ALKYLATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLITIS; DEGENERATIVE DISEASE; HUMAN; LIGAND BINDING; LIVER DISEASE; NONHUMAN; OSTEOPOROSIS; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; SYNTHESIS;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; DRUG DISCOVERY; HUMANS; LIGANDS; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903724896     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666140428105753     Document Type: Article

References (78)

1. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson, A.J. The therapeutic potential of cannabis. Lancet Neurol., 2003, 2, 291-298.
2. Reggio, P.H. Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown. Curr. Med. Chem., 2010, 17, 1468-1486.
3. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564.
4. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
5. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev,. 2006, 58, 389-462.
6. Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol. Rev., 2002, 54, 161-202.
7. Cabral, G.A.; Griffin-Thomas, L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med., 2009, 11, e3.
8. Tanasescu, R.; Constantinescu, C.S. Cannabinoids and the immune system: An overview. Immunobiology, 2010, 215, 588-597.
9. Pertwee, R.G. Pharmacology of Cannabinoid CB1 and CB2 Receptors. Pharmacol. Ther., 1997, 74, 129-180.
10. Guindon, J.; Hohmann, A.G. The endocannabinoid system and cancer: therapeutic implication. Brit. J. Pharmacol., 2011, 163, 1447-1463.
11. Bouaboula, M.; Poinot-Chazel, C.; Bourrie, B.; Canat, X.; Calandra, B.; Rinaldi-Carmona, M.; Le Fur, G.; Casellas, P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J., 1995, 312, 637-641.
12. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrie, B.; Rinaldi-Carmona, M.; Calandra, B.; Le Fur, G.; Casellas, P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Eur. J. Biochem., 1996, 237, 704-711.
13. Parra, S.; Bond, R.A. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Curr. Opin. Pharmacol., 2007, 7, 146-150.
14. Gaoni, Y.; Mechoulam, R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc., 1964, 86, 1646-1647.
15. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science, 1992, 258, 1946-1949.
16. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain. Biochem. Bioph. Res. Co., 1995, 215, 89-97.
17. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 1994, 350, 240-244.
18. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J.-M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Breliere, J.-C.; Le Fur, G. SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor. J. Pharmacol. Exp. Ther., 1998, 284, 644-650.
19. Appendino, G.; Chianese, G.; Taglialatela-Scafati, O. Cannabinoids: Occurrence and Medicinal Chemistry. Curr. Med. Chem., 2011, 18, 1085-1099.
20. Pisanti, S.; Picardi, P.; D'Alessandro, A.; Laezza, C.; Bifulco, M. The endocannabinoid signaling system in cancer. Trends Pharmacol. Sci., 2013, 34, 273-282.
21. Oescha, S.; Gertsch, J. Cannabinoid receptor ligands as potential anticancer agents-high hopes for new therapies? J. Pharm. Pharmacol., 2009, 61, 839-853.
22. Velasco, G.; Sanchez, C.; Guzman, M. Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer, 2012, 12, 436-444.
23. Barnes, M.P. SativexR: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin. Pharmacol., 2006, 7, 607-615.
24. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov., 2008, 7, 438-455.
25. Anand, P.; Whiteside, G.; Fowler, C.J.; Hohmann, A.G. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res. Rev., 2009, 60, 255-266.
26. Giblin, G.M.P.; O'Shaughnessy, C.T.; Naylor, A.; Mitchell, W.L.; Eatherton, A.J.; Slingsby, B.P.; Rawlings, D.A.; Goldsmith, P.; Brown, A.J.; Haslam, C.P.; Clayton, N.M.; Wilson, A.W.; Chessell, I.P.; Wittington, A.R.; Green, R. Discovery of 2-[(2, 4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain. J. Med. Chem., 2007, 50, 2597-2600.
27. Maekawa, T.; Nojima, H.; Kuraishi, Y.; Aisaka, K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur. J. Pharmacol., 2006, 542, 179-183.
28. Odan, M.; Ishizuka, N.; Hiramatsu, Y.; Inagaki, M.; Hashizume, H.; Fujii, Y.; Mitsumori, S.; Morioka, Y.; Soga, M.; Deguchi, M.; Yasui, K.; Arimura, A. Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg. Med. Chem. Lett., 2012, 22, 2803-2806.
29. Bab, I.; Zimmer, A. Cannabinoid receptors and the regulation of bone mass. Brit. J. Pharmacol., 2008, 153, 182-188.
30. Idris, A.I. Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. Curr. Neuropharmacol., 2010, 8, 243-253.
31. Skaper, S.D.; Di Marzo, V. Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Phil. Trans. R. Soc. B, 2012, 367, 3193-3200.
32. Sagredo, O.; Pazos, M.R.; Valdeolivas, S.; Fernandez-Ruiz, J. Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease Recent Pat. CNS Drug Discov., 2012, 7, 41-48.
33. Garcia-Arencibia, M.; Garcia, C.; Fernandez-Ruiz, J. Cannabinoids and Parkinson's Disease. CNS Neurol. Disord.-Dr., 2009, 8, 432-439.
34. Pazos, M.R.; Nunez, E.; Benito, C.; Tolon, R.M.; Romero, J. Role of the endocannabinoid system in Alzheimer's disease: New perspectives. Life Sci., 2004, 75, 1907-1915.
35. Kubajewska, I.; Constantinescu, C.S. Cannabinoids and experimental models of multiple sclerosis. Immunobiology, 2010, 215, 647-657.
36. Tam, J.; Liu, J.; Mukhopadhyay, B.; Cinar, R.; Godlewski, G.; Kunos, G. Endocannabinoids in liver disease. Hepatology, 2011, 53, 346-355.
37. Bermudez-Silva, F.J.; Viveros, M.P.; McPartland, J.M.; Rodriguez de Fonseca, F. The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning? Pharmacol. Biochem. Be., 2010, 95, 375-382.
38. Gelfand, E.V.; Cannon, C.P. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Inv. Drug, 2006, 15, 307-315.
39. Jones, D. End of the line for cannabinoid receptor 1 as an antiobesity target? Nat. Rev. Drug Discov., 2008, 7, 961-962.
40. Muccioli, G.G.; Lambert, D.M. Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin. Ther. Pat., 2006, 16, 1405-1423.
41. Thakur, G.A.; Tichkule, R.; Bajaj, S.; Makriyannis, A. Latest advances in cannabinoid receptor agonists. Expert Opin. Ther. Pat., 2009, 19, 1647-1673.
42. Riether, D. Selective cannabinoid receptor 2 modulators: a patent review 2009-present. Expert Opin. Ther. Pat., 2012, 22, 495-510.
43. Ferrarini, P.L.; Calderone, V.; Cavallini, T.; Manera, C.; Saccomanni, G.; Pani, L.; Ruiu, S.; Gessa, G.L. Synthesis and biological evaluation of 1, 8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. Bioorgan. Med. Chem., 2004, 12, 1921-1933.
44. Manera, C.; Benetti, V.; Castelli, M.P.; Cavallini, T.; Lazzarotti, S.; Pibiri, F.; Saccomanni, G.; Tuccinardi, T.; Vannacci, A.; Martinelli, A.; Ferrarini, P.L. Design, Synthesis, and Biological Evaluation of New 1, 8-Naphthyridin-4(1H)-on-3-carboxamide and Quinolin-4(1H)-on-3-carboxamide Derivatives as CB2 Selective Agonists. J. Med. Chem., 2006, 49, 5947-5957.
45. Manera, C.; Cascio, M.G.; Benetti, V.; Allar, M.; Tuccinardi, T.; Martinelli, A.; Saccomanni, G.; Vivoli, E.; Ghelardini, C.; Di Marzo, V.; Ferrarini, P.L. New 1, 8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg. Med. Chem. Lett., 2007, 17, 6505-6510.
46. Stern, E.; Muccioli, G.G.; Millet, R.; Goossens, J.-F.; Farce, A.; Chavatte, P.; Poupaert, J.H.; Lambert, D.M.; Depreux, P.; Henichart, J.-P. Novel 4-Oxo-1, 4-dihydroquinoline-3-carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling. J. Med. Chem., 2006, 49, 70-79.
47. Stern, E.; Muccioli, G.G.; Bosier, B.; Hamtiaux, L.; Millet, R.; Poupaert, J.H.; Hésnichart, J.-P.; Depreux, P.; Goossens, J.-F.; Lambert, D.M. Pharmacomodulations around the 4-Oxo-1, 4-dihydroquinoline-3-carboxamides, a Class of Potent CB2-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality. J. Med. Chem., 2007, 50, 5471-5484.
48. Botta, L.; Semeraro, T.; Mugnaini, C.; Ligresti, A.; Palazzo, E.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 2. Synthesis and Structure-Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo. J. Med. Chem., 2008, 51, 5075-5084.
49. Pasquini, S.; Ligresti, A.; Mugnaini, C.; Semeraro, T.; Cicione, L.; De Rosa, M.; Guida, F.; Luongo, L.; De Chiaro, M.; Cascio, M.G.; Bolognini, D.; Marini, P.; Pertwee, R.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands. J. Med. Chem., 2010, 53, 5915-5928.
50. Pasquini, S.; De Rosa, M.; Pedani, V.; Mugnaini, C.; Guida, F.; Luongo, L.; De Chiaro, M.; Maione, S.; Dragoni, S.; Frosini, M.; Ligresti, A.; Di Marzo, V.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Anti-Hyperalgesic Effects in Mice. J. Med. Chem., 2011, 54, 5444-5453.
51. Baraldi, P.G.; Saponaro, G.; Moorman, A.R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Ruggiero, E.; Varani, K.; Targa, M.; Vincenzi, F.; Borea, P.A.; Aghazadeh Tabrizi, M. 7-Oxo-[, 4]oxazino[2, 3, 4-ij]quinoline-6-carboxamides as Selective CB2 Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists. J. Med. Chem., 2012, 55, 6608-6623.
52. Mugnaini, C.; Nocerino, S.; Pedani, V.; Pasquini, S.; Tafi, A.; De Chiaro, M.; Bellucci, L.; Valoti, M.; Guida, F.; Luongo, L.; Dragoni, S.; Ligresti, A.; Rosenberg, A.; Bolognini, D.; Cascio, M.G.; Pertwee, R.G.; Moaddel, R.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-Quinolone-3-Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid-2 Receptor Ligands through a Bioisosteric Approach. Chem. Med. Chem., 2012, 7, 920-934.
53. Tabrizi, M.A.; Baraldi, P.G.; Saponaro, G.; Moorman, A.R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Corciulo, C.; Vincenzi, F.; Borea, P.A.; Varani, K. Design, Synthesis, and Pharmacological Properties of New Heteroarylpyridine/Heteroarylpyrimidine Derivatives as CB2 Cannabinoid Receptor Partial Agonists. J. Med. Chem., 2013, 56, 1098-1112.
54. Tabrizi, M.A.; Baraldi, P.G.; Saponaro, G.; Moorman, A.R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Ruggiero, E.; Tintori, C.; Tuccinardi, T.; Vincenzi, F.; Borea, P.A.; Varani, K. Discovery of 7-Oxopyrazolo[1, 5-a]pyrimidine-6-carboxamides as Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists. J. Med. Chem., 2013, 56, 4482-4496.
55. El Bakali, J.; Muccioli, G.G.; Renault, N.; Pradal, D.; Body-Malapel, M.; Djouina, M.; Hamtiaux, L.; Andrzejak, V.; Desreumaux, P.; Chavatte, P.; Lambert, D.M.; Millet, R. 4-Oxo-1, 4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series. J. Med. Chem., 2010, 53, 7918-7931.
56. El Bakali, J.; Gilleron, P.; Body-Malapel, M.; Mansouri, R.; Muccioli, G.G.; Djouina, M.; Barczyk, A.L.; Klupsch, F.d.r.; Andrzejak, V.; Lipka, E.; Furman, C.; Lambert, D.M.; Chavatte, P.; Desreumaux, P.; Millet, R.G. 4-Oxo-1, 4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands Part 2: Discovery of New Agonists Endowed with Protective Effect Against Experimental Colitis. J. Med. Chem., 2012, 55, 8948-8952.
57. Zindell, R.; Walker, E.R.; Scott, J.; Amouzegh, P.; Wu, L.; Ermann, M.; Thomson, D.; Fisher, M.B.; Fullenwider, C.L.; Grbic, H.; Kaplita, P.; Linehan, B.; Patel, M.; Patel, M.; Lobbe, S.; Block, S.; Albrecht, C.; Gemkow, M.J.; Shih, D.-T.; Riether, D. Aryl 1, 4-diazepane compounds as potent and selective CB2 agonists: Optimization of drug-like properties and target independent parameters. Bioorg. Med. Chem. Lett., 2011, 21, 4276-4280.
58. Riether, D.; Wu, L.; Cirillo, P.F.; Berry, A.; Walker, E.R.; Ermann, M.; Noya-Marino, B.; Jenkins, J.E.; Albaugh, D.; Albrecht, C.; Fisher, M.; Gemkow, M.J.; Grbic, H.; Lobbe, S.; Moller, C.; O'Shea, K.; Sauer, A.; Shih, D.-T.; Thomson, D.S. 1, 4-Diazepane compounds as potent and selective CB2 agonists: Optimization of metabolic stability. Bioorg. Med. Chem. Lett., 2011, 21, 2011-2016.
59. Yang, S.-W.; Smotryski, J.; Matasi, J.; Ho, G.; Tulshian, D.; Greenlee, W.J.; Brusa, R.; Beltramo, M.; Cox, K. Structure-activity relationships of 2, 4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain. Bioorg. Med. Chem. Lett., 2011, 21, 182-185.
60. van der Stelt, M.; Cals, J.; Broeders-Josten, S.; Cottney, J.; van der Doelen, A.A.; Hermkens, M.; de Kimpe, V.; King, A.; Klomp, J.; Oosterom, J.; Pols-de Rooij, I.; de Roos, J.; van Tilborg, M.; Boyce, S.; Baker, J. Discovery and Optimization of 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2, 4-dione Derivatives as a Novel Class of Selective Cannabinoid CB2 Receptor Agonists. J. Med. Chem., 2011, 54, 7350-7362.
61. Manley, P.J.; Zartman, A.; Paone, D.V.; Burgey, C.S.; Henze, D.A.; Penna, K.D.; Desai, R.; Leitl, M.D.; Lemaire, W.; White, R.B.; Yeh, S.; Urban, M.O.; Kane, S.A.; Hartman, G.D.; Bilodeau, M.T.; Trotter, B.W. Decahydroquinoline amides as highly selective CB2 agonists: Role of selectivity on in vivo efficacy in a rodent model of analgesia. Bioorg. Med. Chem. Lett., 2011, 21, 2359-2364.
62. Trotter, B.W.; Nanda, K.K.; Burgey, C.S.; Potteiger, C.M.; Deng, J.Z.; Green, A.I.; Hartnett, J.C.; Kett, N.R.; Wu, Z.; Henze, D.A.; Penna, K.D.; Desai, R.; Leitl, M.D.; Lemaire, W.; White, R.B.; Yeh, S.; Urban, M.O.; Kane, S.A.; Hartman, G.D.; Bilodeau, M.T. Imidazopyridine CB2 Agonists: Optimization of CB2/CB1 Selectivity and Implications for In Vivo Analgesic Efficacy. Bioorg. Med. Chem. Lett., 2011, 21, 2354-2358.
63. Worm, K.; Zhou, Q.J.; Saeui, C.T.; Green, R.C.; Cassel, J.A.; Stabley, G.J.; DeHaven, R.N.; Conway-James, N.; LaBuda, C.J.; Koblish, M.; Little, P.J.; Dolle, R.E. Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands. Bioorg. Med. Chem. Lett., 2008, 18, 2830-2835.
64. Goodman, A.J.; Ajello, C.W.; Worm, K.; Bourdonnec, B.L.; Savolainen, M.A.; O'Hare, H.; Cassel, J.A.; Stabley, G.J.; DeHaven, R.N.; LaBuda, C.J.; Koblish, M.; Little, P.J.; Brogdon, B.L.; Smith, S.A.; Dolle, R.E. CB2 selective sulfamoyl benzamides: Optimization of the amide functionality. Bioorg. Med. Chem. Lett., 2009, 19, 309-313.
65. Sellitto, I.; Bourdonnec, B.L.; Worm, K.; Goodman, A.; Savolainen, M.A.; Chu, G.-H.; Ajello, C.W.; Saeui, C.T.; Leister, L.K.; Cassel, J.A.; DeHaven, R.N.; LaBuda, C.J.; Koblish, M.; Little, P.J.; Brogdon, B.L.; Smith, S.A.; Dolle, R.E. Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability. Bioorg. Med. Chem. Lett., 2010, 20, 387-391.
66. Gleave, R.J.; Beswick, P.J.; Brown, A.J.; Giblin, G.M.P.; Haslam, C.P.; Livermore, D.; Moses, A.; Nicholson, N.H.; Page, L.W.; Slingsby, B.; Swarbrick, M.E. 2-Amino-5-aryl-pyridines as selective CB2 agonists: Synthesis and investigation of structure-activity relationships. Bioorg. Med. Chem. Lett., 2009, 19, 6578-6581.
67. Gleave, R.J.; Beswick, P.J.; Brown, A.J.; Giblin, G.M.P.; Goldsmith, P.; Haslam, C.P.; Mitchell, W.L.; Nicholson, N.H.; Page, L.W.; Patel, S.; Roomans, S.; Slingsby, B.P.; Swarbrick, M.E. Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB2 agonists for the treatment of inflammatory pain. Bioorg. Med. Chem. Lett., 2010, 20, 465-468.
68. Hollinshead, S.P.; Astles, P.C.; Chambers, M.G.; Johnson, M.P.; Palmer, J.; Tidwell, M.W. Discovery and optimization of novel purines as potent and selective CB2 agonists. Bioorg. Med. Chem. Lett., 2012, 22, 4962-4966.
69. Nelson, D.W.; Frost, J.M.; Tietje, K.R.; Florjancic, A.S.; Ryther, K.; Carroll, W.A.; Dart, M.J.; Daza, A.V.; Hooker, B.A.; Grayson, G.K.; Fan, Y.; Garrison, T.R.; El-Kouhen, O.F.; Yao, B.; Pai, M.; Chandran, P.; Zhu, C.; Hsieh, G.C.; Meyer, M.D. Synthesis and Evaluation of 2-Amido-3-carboxamide Thiophene CB2 Receptor Agonists for Pain Management. Bioorg. Med. Chem. Lett., 2012, 22, 2604-2608.
70. Thur, Y.; Bhalerao, A.; Munshi, Z.; Pansare, N.; Mann, K.; Hanauer, G.; Kley, H.-P.; Nappe, S.; Weiss-Haljiti, C.; Ostermann, C.; Zitt, C.; Schaefer, M.; Mondal, D.; Ali Siddiki, A.; Armugam, V.; Gudaghe, V.; Gupta, M.; Rayudu, P.; Dautzenberg, F.M.; Das Sarma, K. Structure-activity relationships of 2-arylamido-5, 7-dihydro-4H-thieno[2, 3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action. Bioorg. Med. Chem. Lett., 2012, 22, 7314-7321.
71. Yang, P.; Myint, K.-Z.; Tong, Q.; Feng, R.; Cao, H.; Almehizia, A.A.; Alqarni, M.H.; Wang, L.; Bartlow, P.; Gao, Y.; Gertsch, J.R.; Teramachi, J.; Kurihara, N.; Roodman, G.D.; Cheng, T.; Xie, X.-Q. Lead Discovery, Chemistry Optimization, and Biological Evaluation Studies of Novel Biamide Derivatives as CB2 Receptor Inverse Agonists and Osteoclast Inhibitors. J. Med. Chem., 2012, 55, 9973-9987.
72. Ouyang, Q.; Tong, Q.; Feng, R.; Myint, K.-Z.; Yang, P.; Xie, X.-Q. Trisubstituted Sulfonamides: A New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists. ACS Med. Chem. Lett., 2013, 4, 387-392.
73. Yang, P.; Wang, L.; Feng, R.; Almehizia, A.A.; Tong, Q.; Myint, K.-Z.; Ouyang, Q.; Alqarni, M.H.; Wang, L.; Xie, X.-Q. Novel Triaryl Sulfonamide Derivatives as Selective Cannabinoid Receptor 2 Inverse Agonists and Osteoclast Inhibitors: Discovery, Optimization, and Biological Evaluation. J. Med. Chem., 2013, 56, 2045-2058.
74. Nettekoven, M.; Fingerle, J.; Grether, U.; Gruner, S.; Kimbara, A.; Pullmann, B.; Rogers-Evans, M.; Rover, S.; Schuler, F.; Schulz-Gasch, T.; Ullmer, C. Highly potent and selective cannabinoid receptor 2 agonists: Initial hit optimization of an adamantyl hit series identified from high-through-put screening. Bioorg. Med. Chem. Lett., 2013, 23, 1177-1181.
75. Yrjola, S.; Kalliokoski, T.; Laitinen, T.; Poso, A.; Parkkari, T.; Nevalainen, T. Discovery of novel cannabinoid receptor ligands by a virtual screening approach: Further development of 2, 4, 6-trisubstituted 1, 3, 5-triazines as CB2 agonists. Eur. J. Pharm. Sci., 2013, 48, 9-20.
76. Odan, M.; Ishizuka, N.; Hiramatsu, Y.; Inagaki, M.; Hashizume, H.; Fujii, Y.; Mitsumori, S.; Morioka, Y.; Soga, M.; Deguchi, M.; Akinori Arimura, K.Y. CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: Reduction of CNS side effects by introducing polar functional groups. Bioorg. Med. Chem. Lett., 2012, 22, 2894-2897.
77. Odan, M.; Ishizuka, N.; Hiramatsu, Y.; Inagaki, M.; Hashizume, H.; Fujii, Y.; Mitsumori, S.; Morioka, Y.; Soga, M.; Deguchi, M.; Yasui, K.; Arimura, A. Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent. Bioorg. Med. Chem. Lett., 2012, 22, 2898-2901.
78. Kusakabe, K.-i.; Tada, Y.; Iso, Y.; Sakagami, M.; Morioka, Y.; Chomei, N.; Shinonome, S.; Kawamoto, K.; Takenaka, H.; Yasui, K.; Hamana, H.; Hanasaki, K. Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists. Bioorgan. Med. Chem., 2013, 21, 2045-2055.